Vir Biotechnology (VIR) is back in focus after announcing it will present Phase 2 SOLSTICE trial data for its tobevibart and elebsiran combination in chronic hepatitis delta at the upcoming EASL Congress 2026.

The latest SOLSTICE update comes after a period of strong trading interest, with the share price at $9.19, a 90 day share price return of 23.69% and a 1 year total shareholder return of 104.22%. However, multi year total shareholder returns remain sharply lower, so recent momentum contrasts with longer term losses and may reflect shifting expectations around the pipeline and new partnerships.

If Vir’s hepatitis delta and oncology work has caught your attention, it could be worth broadening your watchlist with other healthcare focused AI opportunities via the 34 healthcare AI stocks.

With Vir trading at $9.19, a recent 1 year total return above 100% and analyst targets implying a sizeable gap to the current price, the key question is whether there is still a buying opportunity or if markets already price in future growth.

Most Popular Narrative: 55.8% Undervalued

Against the last close at $9.19, the most followed narrative points to a fair value of about $20.78, which sets a very different benchmark for Vir.

Vir Biotechnology's ECLIPSE Phase III program in hepatitis delta, which aims to become the new standard of care given the significant unmet medical need and regulatory designations, is expected to potentially drive revenue growth.

The strong foundational patent rights to the PRO-XTEN platform enable expansion into additional high-value oncology indications, potentially increasing earnings through diversification and broadening revenue streams.

Curious what kind of revenue trajectory and profit swing would need to sit behind that fair value, and what sort of future earnings multiple it implies for Vir.

According to the narrative, the fair value estimate of $20.78 is built using a discount rate of 7.25%, with revenue growth and margin improvements doing most of the heavy lifting. Analysts behind this view also factor in Vir remaining loss making for several years, while still applying a very rich future earnings multiple to the company in their long term scenario.

Result: Fair Value of $20.78 (UNDERVALUED)

However, this upbeat story could quickly change if key trials disappoint or if the Brii Biosciences arbitration leads to costly outcomes or partnership setbacks.

Another View: What The P/S Ratio Is Saying

The analyst narrative points to Vir looking undervalued at a fair value of $20.78, but the pricing picture is not one sided. On a P/S basis, the stock trades at 23.7x revenue, which is rich versus the US Biotechs industry at 10.7x and even above its own fair ratio of 0x, though still below a 28.7x peer average. That kind of gap can reflect high expectations as much as opportunity, so the key question is whether you think the current pipeline justifies paying so far ahead of today’s sales.

Next Steps

With such a mixed picture of optimism and concern, it makes sense to review the numbers yourself and decide quickly where you stand. To help frame both sides of the story, start with 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If Vir has sharpened your focus, do not stop there. Use curated stock ideas to spot opportunities and pressure test your portfolio from fresh angles.

• Spot potential mispricings fast by checking out companies flagged in the 48 high quality undervalued stocks.
• Prioritise resilience by scanning stocks highlighted in the 67 resilient stocks with low risk scores.
• Stay ahead of the crowd by reviewing underfollowed opportunities in the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.